Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 9, 2015

View Archived Issues

Cationically modified dextran heparin antidotes show promise in vivo

FDA designates ataluren an orphan drug for aniridia

Shionogi terminates agreement with OncoTherapy Science for peptide vaccine in the ophthalmic field

Juno Therapeutics begins phase II trial of JCAR-015

Batu Biologics begins discovery research in Immittam program

Updated efficacy data reported for L-DOS-47 in NSCLC

Autifony Therapeutics K+ channel modulator improves cognition in schizophrenia model

Mitochondrial DNA mutation linked to mitochondrial hepatopathy

Relaxin levels linked to risk of death in patients with acute heart failure

Strongbridge Biopharma is the new name for Cortendo

Promedior begins phase II study of PRM-151 in IPF

Achillion discloses complement factor D inhibitors

AstraZeneca and University of Manchester launch clinical bioinformatics collaboration

Acetylon presents HDAC6 inhibitors

Piramal patents multikinase inhibitors

Shanghai Haiyan discovers new EFGR inhibitors

Biodim presents bacterial dltA inhibitors

Serendex receives German clearance to initiate phase II trial of molgramostim

Oryzon completes multiple ascending dose portion of phase I trial of ORY-1001

Akebia reports results from phase II trial of vadadustat in CKD-related anemia

Biogen in-licenses Mitsubishi Tanabe's MT-1303 for autoimmune diseases

Topline phase II data on GKT-137831 support development in fibrotic diseases

Topline results from phase III IGNITE2 study of eravacycline for cUTI

Single oral doses of Vitae's VTP-43742 safe in healthy volunteers

Five Prime starts dosing in phase I trial of FPA-008 and nivolumab

FDA grants priority review to alectinib NDA for ALK-positive NSCLC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...